Related Experiment Video

Updated: May 15, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

miR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42

Yuefeng Li1, Xiaolan Zhu, Wenlin Xu

  • 1The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China.

Biochemical and Biophysical Research Communications
|January 23, 2013
PubMed

Insights

MicroRNA-330 (miR-330) inhibits colorectal cancer (CRC) cell growth by down-regulating Cdc42. This finding suggests miR-330 as a potential therapeutic target for CRC progression.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) are key regulators in colorectal carcinoma (CRC) development.
  • The precise miRNA-mRNA interactions in CRC remain incompletely elucidated.
  • Cdc42, a Rho GTPase, is upregulated in CRC and promotes cancer progression.

Purpose of the Study:

  • To investigate the expression and function of miR-330 in colorectal cancer cells.
  • To identify the regulatory relationship between miR-330 and Cdc42.
  • To explore the therapeutic potential of modulating miR-330 in CRC.

Main Methods:

  • Analysis of miR-330 and Cdc42 expression in colorectal cancer cell lines.
  • Experimental manipulation of miR-330 and Cdc42 levels (ectopic expression, knockdown).
  • Assessment of cell proliferation, cell cycle, apoptosis, and in vivo tumor growth.

Main Results:

  • miR-330 expression is inversely correlated with Cdc42 expression in CRC cells.
  • Ectopic miR-330 expression down-regulates Cdc42 at mRNA and protein levels.
  • miR-330 mimics Cdc42 knockdown effects, inhibiting proliferation, inducing G1 arrest and apoptosis.
  • Restoration of Cdc42 partially reverses miR-330's effects.
  • miR-330 suppresses Cdc42 downstream effectors and inhibits tumor growth in vivo.

Conclusions:

  • miR-330 negatively regulates Cdc42 expression and colorectal cancer cell proliferation.
  • Modulating Cdc42 via miR-330 holds potential for influencing CRC progression.
  • miR-330 represents a promising therapeutic target for colorectal cancer treatment.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...